Cardiovascular effects of glucagon-like peptide 1

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 97-105

  Papazafiropoulou, A ^a   Pappas, S I ^a   Papadogiannis, D ^a   Tentolouris, N ^b  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Arterial blood pressure; Cardiovascular; Endothelium; Glucagon like peptide 1; Heart failure; Left ventricular function; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; LIRAGLUTIDE; RECOMBINANT GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR SYSTEM; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DIABETIC PATIENT; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART OUTPUT; HUMAN; HYPERTENSION; NONHUMAN; SATIETY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 78650889026     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955711793564033     Document Type: Article

References (52)

1. Amori, R.E.; Lau, J.; Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic reviewand meta-analysis. JAMA, 2007, 298, 194-206.
2. Preis, S.R.; Hwang, S.J.; Coady, S.; Pencina, M.J.; D'Agostino, R.B.Sr.; Savage, P.J.; Levy, D.; Fox, C.S. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 2009, 119, 1728-1735.
3. Burcelin, R.; Da Costa, A.; Drucker, D.; Thorens, B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes, 2001, 50, 1720-1728.
4. Deacon, C.F.; Hughes, T.E.; Holst, J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes, 1998, 47, 764-769.
5. Deacon, C.F.; Nauck, M.A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Host, J.J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2- terminus in type 2-diabetic patients and in healthy subjects. Diabetes, 1995, 44, 1126-1131.
6. +)- signalling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J. Biol. Chem., 1995, 270, 17749-17757.
7. Wei, Y.; Mojsov, S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett., 1995, 358, 219-224.
8. Drucker, D.J.; Philippe, J.; Mojsov, S.; Chick, W.L.; Habener, J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA., 1987, 84, 3434-3438.
9. Drucker, D.J. The biology of incretin hormones. Cell Metab., 2006, 3, 153-165.
10. Barragán, J.M.; Rodríguez, R.E.; Blázquez, E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1- (7-36) amide in rats. Am. J. Physiol., 1994, 266, 459-466.
11. Barragán, J.M.; Rodríguez, R.E.; Eng, J.; Blázquez, E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul. Pept., 1996, 67, 63-68.
12. Yu, M.; Moreno, C.; Hoagland, K.M.; Dahly, A.; Ditter, K.; Mistry, M.; Roman, R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens., 2003, 21, 1125-1135.
13. Laugero, K.D.; Stonehouse, A.H.; Guss, S.; Landry, J.; Vu, C.; Parkes, D.G. Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome. Metab. Syndr. Relat. Disord., 2009, 7, 327-334.
14. Hirata, K.; Kume, S.; Araki, S.; Sakaguchi, M.; Chin-Kanasaki, M.; Isshiki, K.; Sugimoto, T.; Nishiyama, A.; Koya, D.; Haneda, M.; Kashiwagi, A.; Uzu, T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem. Biophys. Res. Commun,. 2009, 380, 44-49.
15. Barragán, J.M.; Eng, J.; Rodríguez, R.; Blázquez, E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am. J. Physiol., 1999, 277, E784-91.
16. Yamamoto, H.; Lee, C.E.; Marcus, J.N.; Williams, T.D.; Overton, J.M.; Lopez, M.E.; Hollenberg, A.N.; Baggio, L.; Saper, C.B.; Drucker, D.J.; Elmquist, J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest., 2002, 110, 43-52.
17. Isbil-Buyukcoskun, N.; Gulec, G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul. Pept., 2004, 118, 33-38.
18. Cabou, C.; Campistron, G.; Marsollier, N.; Leloup, C.; Cruciani-Guglielmacci, C.; Pénicaud, L.; Drucker, D.J.; Magnan, C.; Burcelin, R. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes, 2008, 57, 2577-2587.
19. Vila Petroff, M.G.; Egan, J.M.; Wang, X.; Sollott, S.J. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ. Res., 2001, 89, 445-452.
20. Nyström, T.; Gonon, A.T.; Sjöholm, A.; Pernow, J. Glucagon-likepeptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept., 2005, 125, 173-177.
21. Gros, R.; You, X.; Baggio, L.L.; Kabir, M.G.; Sadi, A.M.; Mungrue, I.N.; Parker, T.G.; Huang, Q.; Drucker, D.J.; Husain, M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology, 2003, 144, 2242-2252.
22. Kavianipour, M.; Ehlers, M.R.; Malmberg, K.; Ronquist, G.; Ryden, L.; Wikström, G.; Gutniak, M. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides, 2003, 24, 569-578.
23. Nikolaidis, L.A.; Elahi, D.; Hentosz, T.; Doverspike, A.; Huerbin, R.; Zourelias, L.; Stolarski, C.; Shen, Y.T.; Shannon, R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation, 2004, 110, 955-961.
24. Nikolaidis, L.A.; Elahi, D.; Shen, Y.T.; Shannon, R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, H2401-408.
25. Nikolaidis, L.A.; Doverspike, A.; Hentosz, T.; Zourelias, L.; Shen, Y.T.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reper fusion in conscious canines. J. Pharmacol. Exp. Ther., 2005, 312, 303-308.
26. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Brand, C.L.; Yellon, D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes, 2005, 54, 146-151.
27. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Yellon, D.M. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reper fusion in an isolated rat heart model. Cardiovasc. Drugs Ther., 2005, 19, 9-11.
28. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Yellon, D.M. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc. Drugs Ther., 2007, 21, 253-256.
29. Zhao, T.; Parikh, P.; Bhashyam, S.; Bolukoglu, H.; Poornima, I.; Shen, Y.T.; Shannon, R.P. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther., 2006, 317, 1106-1113.
30. Sonne, D.P.; Engstrøm, T.; Treiman, M. Protective effects of GLP- 1 analogues exendin-4 and GLP-1(9-36) amide against ischemia reperfusion injury in rat heart. Regul. Pept., 2008, 146, 243-249.
31. Timmers, L.; Henriques, J.P.; de Kleijn, D.P.; Devries, J.H.; Kemperman, H.; Steendijk, P.; Verlaan, C.W.; Kerver, M.; Piek, J.J.; Doevendans, P.A.; Pasterkamp, G.; Hoefer, I.E. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol., 2009, 53, 501-510.
32. Xie, Y.; Wang, S.X.; Sha, W.W.; Zhou, X.; Wang, W.L.; Han, L.P.; Li, D.Q.; Yu, D.M. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia reoxygenation. Chin Med. J. (Engl).,2008, 121, 2134-2138.
33. Huisamen, B.; Genade, S.; Lochner, A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc. J. Afr., 2008, 19, 77-83.
34. Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagons like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117, 2340-2350.
35. Noyan-Ashraf, M.H.; Momen, M.A.; Ban, K.; Sadi, A.M.; Zhou, Y.Q.; Riazi, A.M.; Baggio, L.L.; Henkelman, R.M.; Husain, M.; Drucker, D.J. The GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes Following Experimental Myocardial Infarction in Mice. Diabetes, 2009, 58, 975-983.
36. Nyström, T.; Gutniak, M.K.; Zhang, Q.; Zhang, F.; Holst, J.J.; Ahrén, B.; Sjöholm, A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab., 2004, 287, E1209-215.
37. Thrainsdottir, I.; Malmberg, K.; Olsson, A.; Gutniak, M.; Rydén, L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res., 2004, 1, 40-43.
38. Sokos, G.G.; Nikolaidis, L.A.; Mankad, S.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail., 2006, 12, 694-699.
39. Sokos, G.G.; Bolukoglu, H.; German, J.; Hentosz, T.; Magovern, G.J; Benckart, D.H.; Elahi, D.; Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol., 2007, 100, 824-829.
40. Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109, 962-965.
41. Gutzwiller, J.P.; Tschopp, S.; Bock, A.; Zehnder, C.E.; Huber, A.R.; Kreyenbuehl, M.; Gutmann, H.; Drewe, J.; Henzen, C.; Goeke, B.; Beglinger, C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab., 2004, 89, 3055-3061.
42. Bharucha, A.E.; Charkoudian, N.; Andrews, C.N.; Camilleri, M.; Sletten, D.; Zinsmeister, A.R.; Low, P.A. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2008, 295, R874-80.
43. Basu, A.; Charkoudian, N.; Schrage, W.; Rizza, R.A.; Basu, R.; Joyner, M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab., 2007, 293, E1289-295.
44. Halbirk, M.; Nørrelund, H.; Møller, N.; Holst, J.J.; Schmitz, O.; Nielsen, R.; Nielsen-Kudsk, J.E.; Nielsen, S.S.; Nielsen, T.T.; Eiskjaer, H.; Bøtker, H.E.; Wiggers, H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol., 2010, 298, H1096-102.
45. Buteau, J.; Roduit, R.; Susini, S.; Prentki, M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3- kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)- cells. Diabetologia, 1999, 42, 856-864.
46. Hausenloy, D.J.; Yellon, D.M. New directions for protecting the heart against ischemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc. Res., 2004, 61. 448-460.
47. Tong, H.; Chen, W.; Steenbergen, C.; Murphy, E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ. Res., 2000, 87, 309-315.
48. Mocanu, M.M.; Bell, R.M.; Yellon, D.M. PI3 kinase and not p44/42 appears to be implicated in the protection conferred by ischemic preconditioning. J. Mol. Cell Cardiol., 2002, 34, 661-668.
49. Deacon, C.F.; Pridal, L.; Klarskov, L.; Olesen, M.; Holst, J.J. Glucagon-like peptide-1 undergoes differential tissue specific metabolism in the anesthetized pig. Am. J. Physiol., 1996, 271, E458-64.
50. Toft-Nielsen, M.B.; Madsbad, S.; Holst, J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care, 1999, 22, 1137-1143.
51. Klonoff, D.C.; Buse, J.B.; Nielsen, L.L.; Guan, X.; Bowlus, C.L.; Holcombe, J.H.; Wintle, M.E.; Maggs, D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin., 2008, 24, 275-286.
52. Vilsbøll, T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Exp. Opin. Invest. Drug, 2007, 16, 231-237.